Start Date
6-24-2013 8:45 AM
End Date
6-24-2013 9:30 AM
Description
Kim A. Caldwell, RPh
Employed by Humana Inc., Kim is the Director of Pharmacy Professional Affairs for Humana Pharmacy Solutions. In this role, he and his team serve to liaison between HPS business owners, Humana Public Affairs, and key professional and trade partners. They serve as the pharmacy subject matter experts aligned with key business and regulatory issues, including visits with members of federal and state legislatures as well as the interface with state boards of pharmacy and key trade organizations. Previously, he started and directed Competitive Health Analytics, Inc. (CHA) a business unit within Humana Inc. for the first four years of operations. As an evidence-based research group focusing on key healthcare questions in collaboration with private, public, and internal research partners, using the comprehensive Humana database, CHA engaged in extensive work relating to comparative effectiveness research, post-marketing surveillance, return-on-investment queries, and numerous scenario-based healthcare studies.
Included in
Out-of-Pocket Costs and Prescription Reversals: the case of Oral Linezolid
Kim A. Caldwell, RPh
Employed by Humana Inc., Kim is the Director of Pharmacy Professional Affairs for Humana Pharmacy Solutions. In this role, he and his team serve to liaison between HPS business owners, Humana Public Affairs, and key professional and trade partners. They serve as the pharmacy subject matter experts aligned with key business and regulatory issues, including visits with members of federal and state legislatures as well as the interface with state boards of pharmacy and key trade organizations. Previously, he started and directed Competitive Health Analytics, Inc. (CHA) a business unit within Humana Inc. for the first four years of operations. As an evidence-based research group focusing on key healthcare questions in collaboration with private, public, and internal research partners, using the comprehensive Humana database, CHA engaged in extensive work relating to comparative effectiveness research, post-marketing surveillance, return-on-investment queries, and numerous scenario-based healthcare studies.
